MALDEN, Mass., Aug. 7, 2019 /PRNewswire-PRWeb/ -- On Thursday, August 8, 2019, NanoFUSE Biologics will launch its one-of-a-kind biologic in Panama City, Panama. NanoFUSE is working in conjunction with its new partner PTY Medical Group to continue its global launch of the FDA-cleared, patented biologic.
The NanoFUSE event will unite more than 40 top orthopedic and spine surgeons to further inform them about the features and characteristics of the unique biologic. The launch will take place at the Sortis Hotel at 7:30 pm.
NanoFUSE Biologics is the only bioactive glass that is FDA-cleared to be combined with DBM. Bioactive glass has been clinically proven in orthopedics for over 30 years, but NanoFUSE Biologics is the first to use bioactive glass to create a revolutionary and patented biologic.
Philip Hamann, NanoFUSE's VP of Sales in Latin America, Spain & Portugal, Archie Yamada, NanoFUSE's VP Product Business Development, and Gustavo Pinilla, PTY Medical Group General Manager, will present at the event.
Philip Hamann said, "Introducing NanoFUSE to Panama represents the beginning of many more launches in the region. As we move forward and work with strategic partners, I have no doubt that NanoFUSE will be the number one biologic solution for not just surgeons, but also for their patients. Our commercial partner in Panama, PTY, has done a great job organizing this top-notch event. NanoFuse's effort to position itself in Panama is just one more step in its global expansion."
Jake Lubinski, President of NanoFUSE said, "NanoFUSE is clinically proven and reduces the need for autograft. We're proud to offer the highest quality of DBM and synthetic biologics to treat patients in Panama. The recent release of our 100% fully synthetic bioactive glass strip, NanoSTRIP positions NanoFUSE to be the worldwide leader in bioactive glass and synthetic biologics."
To attend this NanoFUSE event in Panama, or to learn how you can start using NanoFUSE, please contact Rosa Martinez at [email protected].
About NanoFUSE Biologics
NanoFUSE is the synergistic blend of osteoinductive DBM combined with the osteostimulative properties of bioactive glass. NanoFUSE is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in all orthopedic surgery. NanoFUSE Biologics is a KICVentures portfolio company and is distributed by SpineFrontier.
KICVentures is a private investment holding company founded by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities and has a proven track-record of building the most disruptive spine technology portfolio, including AxioMed, NanoFUSE and SpineFrontier. It has headquarters in Boston, MA.
SOURCE NanoFUSE Biologics